Russell Wilson
Keine laufenden Positionen mehr
Profil
Zurzeit ist Russell P. Wilson Senior Vice President-Business Development bei Novavax, Inc. Zuvor hatte er die Position des Chief Financial Officer & Vice President bei Supernus Pharmaceuticals, Inc. inne, die des Chief Financial Officer, Secretary & Senior VP bei Intercell USA, Inc. und die des General Counsel bei North American Vaccine, Inc. Er erwarb einen MBA und einen Hochschulabschluss an der University of Virginia und einen Bachelor-Abschluss an der Princeton University.
Ehemalige bekannte Positionen von Russell Wilson
| Unternehmen | Position | Ende |
|---|---|---|
| NOVAVAX, INC. | Chief Tech/Sci/R&D Officer | 28.03.2012 |
| IOMAI CORPORATION | Director of Finance/CFO | 01.08.2008 |
North American Vaccine, Inc.
 North American Vaccine, Inc. Pharmaceuticals: OtherHealth Technology North American Vaccine, Inc. develops and sells vaccines for the prevention of infectious diseases. The company is based in Columbia, MD. The company was founded by Jeffrey G. Spragens. North American Vaccine was acquired by Baxter International, Inc. on June 27, 2000 for $250.67 million. | General Counsel | 01.01.2000 |
| SUPERNUS PHARMACEUTICALS, INC. | Director of Finance/CFO | - |
Ausbildung von Russell Wilson
| University of Virginia | Graduate Degree |
| Princeton University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NOVAVAX, INC. | Health Technology |
| SUPERNUS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
North American Vaccine, Inc.
North American Vaccine, Inc. Pharmaceuticals: OtherHealth Technology North American Vaccine, Inc. develops and sells vaccines for the prevention of infectious diseases. The company is based in Columbia, MD. The company was founded by Jeffrey G. Spragens. North American Vaccine was acquired by Baxter International, Inc. on June 27, 2000 for $250.67 million. | Health Technology |
Intercell USA, Inc.
 Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
